Literature DB >> 10406801

VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells.

T Asahara1, T Takahashi, H Masuda, C Kalka, D Chen, H Iwaguro, Y Inai, M Silver, J M Isner.   

Abstract

Vascular endothelial growth factor (VEGF) has been shown to promote neovascularization in animal models and, more recently, in human subjects. This feature has been assumed to result exclusively from its direct effects on fully differentiated endothelial cells, i.e. angiogenesis. Given its regulatory role in both angiogenesis and vasculogenesis during fetal development, we investigated the hypothesis that VEGF may modulate endothelial progenitor cell (EPC) kinetics for postnatal neovascularization. Indeed, we observed an increase in circulating EPCs following VEGF administration in vivo. VEGF-induced mobilization of bone marrow-derived EPCs resulted in increased differentiated EPCs in vitro and augmented corneal neovascularization in vivo. These findings thus establish a novel role for VEGF in postnatal neovascularization which complements its known impact on angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10406801      PMCID: PMC1171472          DOI: 10.1093/emboj/18.14.3964

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  416 in total

1.  Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization.

Authors:  T Murohara; H Ikeda; J Duan; S Shintani; K i Sasaki; H Eguchi; I Onitsuka; K Matsui; T Imaizumi
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

2.  Circulating endothelial precursors: mystery, reality, and promise.

Authors:  S Rafii
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

Review 3.  Physiology of angiogenesis.

Authors:  H Kurz
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

4.  HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells.

Authors:  J Llevadot; S Murasawa; Y Kureishi; S Uchida; H Masuda; A Kawamoto; K Walsh; J M Isner; T Asahara
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

Review 5.  Angiogenesis in hematologic malignancies and its clinical implications.

Authors:  Renchi Yang; Zhong Chao Han
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

6.  Modeling the early stages of vascular network assembly.

Authors:  Guido Serini; Davide Ambrosi; Enrico Giraudo; Andrea Gamba; Luigi Preziosi; Federico Bussolino
Journal:  EMBO J       Date:  2003-04-15       Impact factor: 11.598

7.  Inhibition of endothelial cell survival and angiogenesis by protein kinase A.

Authors:  Semi Kim; Manjiri Bakre; Hong Yin; Judith A Varner
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

Review 8.  CD34-positive stem cells: in the treatment of heart and vascular disease in human beings.

Authors:  Alexander R Mackie; Douglas W Losordo
Journal:  Tex Heart Inst J       Date:  2011

9.  Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization.

Authors:  Daniel J Nolan; Alessia Ciarrocchi; Albert S Mellick; Jaspreet S Jaggi; Kathryn Bambino; Sunita Gupta; Emily Heikamp; Michael R McDevitt; David A Scheinberg; Robert Benezra; Vivek Mittal
Journal:  Genes Dev       Date:  2007-06-15       Impact factor: 11.361

10.  Wnt1 expression induces short-range and long-range cell recruitments that modify mammary tumor development and are not induced by a cell-autonomous beta-catenin effector.

Authors:  Young Chul Kim; Rod J Clark; Erik A Ranheim; Caroline M Alexander
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.